Liquidia Technologies, Inc. (LQDA) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Bronstein, Gewirtz & Grossman, is investigating potential claims against Liquidia Technologies, Inc. (NASDAQ: LQDA) on behalf of investors. The investigation follows Liquidia's announcement on August 19, 2024, that the FDA granted tentative approval for YUTREPIA™ (treprostinil) inhalation powder for treating PAH and PH-ILD in adults. However, final approval is delayed due to a competing product's regulatory exclusivity. This news caused Liquidia's stock to drop 30.62%, closing at $9.79 per share. Investors who purchased LQDA securities are encouraged to participate in the investigation. The law firm is operating on a contingency fee basis, seeking reimbursement only if successful.
Bronstein, Gewirtz & Grossman sta indagando su potenziali reclami contro Liquidia Technologies, Inc. (NASDAQ: LQDA) per conto degli investitori. L'indagine segue l'annuncio di Liquidia del 19 agosto 2024, secondo cui la FDA ha concesso approvazione preliminare per YUTREPIA™ (treprostinil) in polvere per inalazione per il trattamento della PAH e PH-ILD negli adulti. Tuttavia, l'approvazione finale è ritardata a causa dell'esclusività normativa di un prodotto concorrente. Questa notizia ha causato un calo del 30,62% del titolo Liquidia, che ha chiuso a $9.79 per azione. Gli investitori che hanno acquistato titoli LQDA sono incoraggiati a partecipare all'indagine. Lo studio legale opera su base di onorario di successo, richiedendo un rimborso solo in caso di successo.
Bronstein, Gewirtz & Grossman está investigando posibles reclamaciones contra Liquidia Technologies, Inc. (NASDAQ: LQDA) en nombre de los inversores. La investigación sigue al anuncio de Liquidia del 19 de agosto de 2024, en el cual la FDA otorgó aprobación provisional para YUTREPIA™ (treprostinil) en polvo para inhalación para el tratamiento de PAH y PH-ILD en adultos. Sin embargo, la aprobación final se ha retrasado debido a la exclusividad regulatoria de un producto competidor. Esta noticia llevó a que las acciones de Liquidia cayeran un 30.62%, cerrando a $9.79 por acción. Se anima a los inversores que compraron valores de LQDA a participar en la investigación. El bufete de abogados opera bajo la base de honorarios contingentes, buscando reembolso solo si tiene éxito.
Bronstein, Gewirtz & Grossman은 투자자를 대신하여 Liquidia Technologies, Inc. (NASDAQ: LQDA)에 대한 잠재적 소송을 조사하고 있습니다. 이 조사는 Liquidia가 2024년 8월 19일 FDA가 성인 PAH 및 PH-ILD 치료를 위한 YUTREPIA™ (treprostinil) 흡입 분말에 대해 임시 승인을 발표한 이후 진행되고 있습니다. 그러나 최종 승인은 지연되었습니다 경쟁 제품의 규제 독점으로 인해 발생했습니다. 이 소식은 Liquidia의 주가를 30.62% 하락시켰으며 주가는 $9.79로 마감했습니다. LQDA 증권을 구입한 투자자들은 조사를 참여하도록 권장됩니다. 이 법률 사무소는 성과 수수료 기반으로 운영되며, 성공한 경우에만 보상을 요구합니다.
Bronstein, Gewirtz & Grossman investigue des revendications potentielles contre Liquidia Technologies, Inc. (NASDAQ: LQDA) au nom des investisseurs. L'enquête fait suite à l'annonce de Liquidia le 19 août 2024, selon laquelle la FDA a accordé une approbation temporaire pour YUTREPIA™ (treprostinil) poudre d'inhalation pour le traitement de la PAH et de la PH-ILD chez les adultes. Cependant, l'approbation finale est retardée en raison de l'exclusivité réglementaire d'un produit concurrent. Cette nouvelle a provoqué une baisse de 30,62% de l'action de Liquidia, qui a clôturé à 9,79 $ par action. Les investisseurs ayant acheté des titres LQDA sont encouragés à participer à l'enquête. Le cabinet d'avocats fonctionne sur la base d'honoraires conditionnels, demandant un remboursement uniquement en cas de succès.
Bronstein, Gewirtz & Grossman untersucht potenzielle Ansprüche gegen Liquidia Technologies, Inc. (NASDAQ: LQDA) im Namen von Investoren. Die Untersuchung folgt der Ankündigung von Liquidia am 19. August 2024, dass die FDA vorläufige Genehmigung für YUTREPIA™ (treprostinil) Inhalationspulver zur Behandlung von PAH und PH-ILD bei Erwachsenen erteilt hat. Allerdings ist die endgültige Genehmigung verzögert aufgrund der regulatorischen Exklusivität eines konkurrierenden Produkts. Diese Nachrichten führten dazu, dass die Liquidia-Aktien um 30,62% gefallen sind und bei $9,79 pro Aktie schlossen. Investoren, die LQDA-Wertpapiere gekauft haben, werden ermutigt, an der Untersuchung teilzunehmen. Die Kanzlei arbeitet auf Basis einer Erfolgshonorierung und fordert eine Rückerstattung nur im Erfolgsfall.
- FDA granted tentative approval for YUTREPIA™ (treprostinil) inhalation powder
- YUTREPIA™ targets treatment for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)
- Final FDA approval for YUTREPIA™ delayed due to competing product's regulatory exclusivity
- Stock price fell 30.62% ($4.32 per share) following the announcement
- Potential legal claims being investigated against the company
Insights
The investigation into Liquidia Technologies raises significant concerns for investors. The 30.62% stock price drop following the FDA's tentative approval of YUTREPIA™ is a substantial market reaction. This decline suggests investors were expecting full approval, not just tentative approval pending regulatory exclusivity expiration.
The key issue here is the timing of final approval. Without a clear timeline for the competing product's exclusivity expiration, Liquidia faces uncertainty in bringing YUTREPIA™ to market. This delay could impact revenue projections and market position, potentially affecting long-term valuation.
Investors should closely monitor any developments regarding the competing product's exclusivity and Liquidia's strategies to navigate this regulatory hurdle. The investigation may uncover additional information about the company's disclosures and handling of the approval process, which could have further implications for shareholder value.
The market's sharp reaction to Liquidia's news underscores the critical importance of regulatory approvals in the biotech sector. The
Investors should consider the potential impact on Liquidia's cash runway and future financing needs. With YUTREPIA™'s launch delayed, the company may need to extend its financial resources or seek additional funding, which could lead to dilution for existing shareholders.
Looking ahead, the key metrics to watch will be Liquidia's burn rate, cash position and any updates on the timeline for final approval. The company's ability to manage costs and potentially pivot to other revenue streams during this waiting period will be important for its financial health and stock performance.
NEW YORK CITY, NY / ACCESSWIRE / August 27, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Liquidia Technologies, Inc. ("Liquidia" or "the Company") (NASDAQ:LQDA). Investors who purchased Liquidia securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LQDA.
Investigation Details
On August 19, 2024, Liquidia issued a press release announcing that "the U.S. Food and Drug Administration (FDA) has granted tentative approval of YUTREPIA™ (treprostinil) inhalation powder to treat adults with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)" but "must await the expiration of regulatory exclusivity of a competing product before final approval can be granted." On this news, Liquidia's stock price fell
What's Next?
If you are aware of any facts relating to this investigation or purchased Liquidia securities, you can assist this investigation by visiting the firm's site: bgandg.com/LQDA. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com
SOURCE: Bronstein, Gewirtz & Grossman, LLC
View the original press release on accesswire.com
FAQ
What caused Liquidia Technologies (LQDA) stock to drop on August 19, 2024?
What is the current status of Liquidia's (LQDA) YUTREPIA™ drug approval?
Why is Bronstein, Gewirtz & Grossman investigating Liquidia Technologies (LQDA)?
How can investors participate in the Liquidia Technologies (LQDA) investigation?
